We receive funding from a variety of sources that recognize the value of our high-impact research.
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology. Yongho Bae (Principal Investigator). NIH/NHLBI. $2,266,072. 9/1/2023-8/1/2027.
Immunomodulatory Therapy After Resuscitation From Cardiac Arrest. Olga Pletnikova (Consultant). NIH. 1/1/2022-12/1/2026.
Disrupting ion channel scaffolding to treat neuropathic pain. Tracey Ignatowski (Co-Investigator). NIH. $1,901,926. 9/1/2019-8/1/2024.
Quantitative Risk Model for Predicting Likelihood of Recurrence for Oral Cavity Cancer. Scott Doyle (Principal Investigator). NIH. $2,003,024. 4/1/2020-3/1/2024.
On the Control of Neuronal Networks through Light-mediated Programming of Genomic Networks. Michal Stachowiak (Principal Investigator). National Science Foundation. 3/1/2021-3/1/2024.
Collaborative Research: Control of Information Processing and Learning in Neuronal Networks through Light-mediated Programming of Genomic Networks. Yongho Bae (Co-Principal Investigator). National Science Foundation. $366,284. 2/1/2021-1/1/2024.
Drug Development Project. Yongho Bae (Principal Investigator). Empire Discovery Institute. $250,000. 11/1/2022-11/1/2023.
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology. Yongho Bae (Principal Investigator). NIH/NHLBI. $639,543. 9/1/2022-8/1/2023.
Biomarker Discovery and Validation in PSP. Olga Pletnikova (Contributor). NIH. $576,476. 8/1/2018-4/1/2023.
Networked Nanophotonic Devices for Stem Cell Regulation: From Optogenetics to Optogenomics. Yongho Bae (Co-Principal Investigator). National Science Foundation. $599,067. 8/1/2017-7/1/2022.
Mechanotransduction in Vascular Smooth Muscle: Survivin as a Mediator of Stiffness-Induced Responses. Yongho Bae (Principal Investigator). American Heart Association. $266,000. 7/1/2018-6/1/2022.
“Networked Nanophotonic Devices for Stem Cell Regulation:From Optogenetics to Optogenomics. Michal Stachowiak (Co-Principal Investigator). National Science Foundation. 9/1/2017-9/1/2021.
SBIR Phase II “A Blood-Based Test to Identify Patients with Intracranial Aneurysm”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $24,891. 8/1/2019-7/1/2021.
Computerized histologic image predictor of cancer outcome. John Tomaszewski (Co-Investigator). NIH/Case. $232,187. 7/1/2016-6/1/2021.
University at Buffalo’s Center for Advanced Technology in Big Data and Health Sciences Total (UBCAT) “Molecular Markers for Dangerous Intracranial Aneurysms”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $17,387. 7/1/2020-6/1/2021.
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker The goal of this study to clarify mechanism of TDP-43 proteinopathy and perform target validation studies and develop biomarkers for ALS-FTD. Olga Pletnikova (Contributor). NIH. $250,000. 4/1/2016-3/1/2021.
Szigeti K, Ihnatovych I, Rosas N, Dorn RP, Notari E, Cortes Gomez E, He M, Maly I, Prasad S, Nimmer E, Heo Y, Fuchsova B, Bennett DA, Hofmann WA, Pralle A, Bae Y, Wang J. (2023) Neuronal actin cytoskeleton gain of function in the human brain. EBioMedicine (Sep), 95: 104725. doi:10.1016/j.ebiom.2023.104725